Ono Pharmaceutical Co.-Un ADROPHLY
13F holders, Q2 2024 (June 30)3holders
0new positions
0sold out
$4.55avg. 13F price*
At the end of Q2 2024, 3 institutions reported holding Ono Pharmaceutical Co.-Un ADR (OPHLY) in their 13F filings, unchanged from Q1 2024. 0 opened new positions and 0 sold out. The largest holders were Rhumbline Advisers ($104K), GAMMA Investing LLC ($9K) and PNC Financial Services Group, Inc. ($278).
- Company
- Ono Pharmaceutical Co.-Un ADR
- CUSIP
- 682736103
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 7,492 shares bought and 4,817 shares sold, net +2,675 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Rhumbline Advisers | 0.00% | Add +49.0% | 22,767 | $104K |
| GAMMA Investing LLC | 0.00% | Reduce -71.6% | 1,905 | $9K |
| PNC Financial Services Group, Inc. | 0.00% | Reduce -16.4% | 61 | $278 |
"% of holder's portfolio" is OPHLY's weight in each manager's 13F, not the share of Ono Pharmaceutical Co.-Un ADR the manager owns.